I
mmune checkpoint blockade has shown limited benefit in prostate cancer in several studies. [1] [2] [3] Nonetheless, durable objective responses have been reported, suggesting that patients with molecularly defined subsets of prostate cancer may benefit from this therapeutic approach. [4] [5] [6] Pembrolizumab, an antibody targeting the programmed cell death protein 1 (PD-1) receptor, recently earned accelerated approval by the US Food and Drug Administration for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, independent of site of origin. Detection of MSI thus represents the first clinical indication for prospective tumor profiling in patients with prostate cancer. 7 However, the optimal method for determining MSI-H/dMMR status in patients with prostate cancer and the clinical implications of broader screening for this phenotype remain unknown. The prevalence of MSI-H/dMMR prostate cancer is unclear, with frequencies ranging from 1.2% to 12.0% in prior reports. 8, 9 Recent sequencing studies of metastatic castrationresistant prostate cancer (mCRPC) showed that 2% to 3% of tumors have a higher mutation burden that is often associated with genomic alterations in MMR-associated genes, suggesting that tumor sequencing may be an efficient method for identifying MSI-H/dMMR prostate cancer. 10,11 Herein, we leveraged a prospectively generated genomic data set of 1551 prostate tumors from 1346 patients to define the frequency of MSI-H/dMMR prostate cancer and report outcomes for patients with MSI-H/dMMR mCRPC who were treated with anti-PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy.
Methods

Patients and Samples
From January 1, 2015, through January 31, 2018, 1551 tumors from 1346 patients with prostate cancer treated at Memorial Sloan Kettering Cancer Center, New York, New York, underwent clinical genomic profiling with a hybridization capturebased next-generation sequencing assay (Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT]). 12,13 Patients were given the option to consent to secondary germline analysis. Immunohistochemical (IHC) analysis for MSH2 (OMIM 609309), MSH6 (OMIM 600678), MLH1 (OMIM 600678), and PMS2 (OMIM 600259) was performed on select tumors. Medical record review for patient clinical characteristics and outcomes, with follow-up until May 31, 2018, was performed under a protocol approved by the institutional review board of Memorial Sloan Kettering Cancer Center, with a waiver of consent for the analysis of deidentified data.
Sequencing and Analysis
Tumors and matched normal blood samples were sequenced as previously described. 10, 13 An algorithm for the detection of somatic microsatellite changes using paired tumornormal sequence data (MSIsensor) 14, 15 was applied to all tumors, yielding a quantitative MSIsensor score. Tumors deemed to have inadequate tumor content or quality (<200 × median exon coverage, <10% median exonic variant allele frequency, or no mutations with ≤20% tumor content on pathologic review) were flagged, and their MSIsensor scores were excluded from the primary analysis. Tumor mutation burden (TMB) was calculated as mutations per megabase (mut/Mb). Mutational signature analysis 16, 17 (eMethods in the Supplement) was performed for tumors with somatic mutation counts of at least 10. Alterations in MMR genes were considered deleterious and likely oncogenic if they were pathogenic or likely pathogenic alterations present in the germline 18, 19 or if they were somatic truncating mutations or deletions. 20 For statistical analysis, comparison of MSI-H/dMMR frequency between disease subsets was performed using a 2-tailed Fisher exact text.
Results
Identification of MSI-H/dMMR in Prostate Cancer Using Next-Generation Sequencing
A total of 1551 tumors from 1346 patients with prostate cancer underwent prospective sequencing. 10,13 Forty-seven tumors (3.0%) were hypermutated, defined herein as a TMB of at least 10 mut/Mb. 10, 11 To assess for MSI, we calculated MSIsensor scores 14, 15 for all samples. Notably, 384 tumors (24.8% of the total) were excluded from the primary MSIsensor analysis owing to low tumor purity (eTable 1 in the Supplement), which can affect MSIsensor score reliability. 14 Thus, 1167 tumors from 1033 patients (mean [SD] age, 65.6 [9.3] years) were considered adequate for MSIsensor assessment ( Figure 1A) . We classified MSIsensor scores as high (≥10), indeterminate (≥3 to <10), or low (<3) based on a large, retrospective pancancer analysis comparing MSIsensor score with orthogonal methods 14 ( Figure 1B ). Twenty-three of 1033 patients (2.2%)
had tumors with MSIsensor scores of at least 10 and were thus classified as having MSI-H disease. All MSI-H tumors had a TMB of at least 10 mut/Mb and evidence of MMR protein loss by IHC or a deleterious alteration in an MMR gene with the exception of 1 patient (P-0010034), who had a high TMB (22.6 mut/further characterize these tumors, we reviewed each case for deleterious alterations in MMR genes, and in tumors for which adequate tissue was available, we performed IHC to assess for MMR protein loss ( Figure 2 ). Within this subset, tumors were classified as MSI-H/dMMR if they were found to harbor a deleterious germline or somatic alteration in an MMR gene or had MMR protein loss on IHC findings. Of the 28 patients with MSIsensor-indeterminate scores, 9 met these criteria and were considered to have MSI-H/dMMR prostate cancer. These patients typically had high TMBs and evidence of a predominant MSI/ MMR signature on mutational signature decomposition ( Figures 1B and 2 ). All patients who were identified as having MSI-H/dMMR tumors based on a deleterious MMR gene alteration were confirmed to have evidence of biallelic loss (eTable 1 in the Supplement). In total, 32 of 1033 patients (3.1%) met the criteria defined above for MSI-H/dMMR prostate cancer (eFigures 1A and 2 in the Supplement). The disease state at the time of tumor collection and the frequencies of MSI-H/dMMR in disease subsets are shown in eFigure 3 in the Supplement.
Of note, 7 of the 1033 patients (0.7%) had a deleterious MMR gene alteration (1 germline and 6 somatic) without evidence of MSI or hypermutation (eTables 1 and 3 in the Supplement).
As outlined above, 384 prostate tumors (24.8%) with quality scores sufficiently high for mutational calling had insufficient sequence coverage or tumor purity for MSIsensor analysis. We reviewed these tumors to assess whether orthogonal measures, such as TMB, IHC, or mutational signature decomposition, could help guide clinical decision making in these cases. In total, 9 of 313 patients (2.9%) with inadequate tissue quality for MSIsensor analysis had high TMB and/or a somatic mutation in an MMR-associated gene. Two patients (P-00021600 and P-0024488) had TMBs greater than 20 mut/Mb and were found to have loss of MMR proteins on IHC analysis, consistent with dMMR (eTable 1 in the Supplement). Based on these results, in cases where tumor purity limits MSIsensor assessment, we now recommend confirmatory IHC for tumors with a high TMB or a deleterious alteration in an MMR gene (eFigure 4 in the Supplement).
Germline Alterations in MMR Genes and MSI-H/dMMR Status
Mismatch repair-deficient prostate cancer has been reported to occur at increased frequency in Lynch syndrome mutation carriers. 21 We sought to determine the rate of germline alterations in MMR genes in patients with MSI-H/dMMR prostate cancer who were identified through tumor profiling. Seven of the 32 patients with MSI-H/dMMR disease (21.9%) had a pathogenic or likely pathogenic germline mutation in an MMRassociated gene (eFigure 1B in the Supplement), including 5 in MSH2,1inMSH6,and1inPMS2. One additional patient had a pathogenic germline mutation in MSH6 but no evidence of MSI or hypermutation in his tumor, suggesting that the pathogenic MSH6 mutation did not contribute to the pathogenesis of his prostate cancer (eTable 3 in the Supplement).
Analysis of Longitudinally Profiled Patients
As outlined above, 21.9% of patients with MSI-H/dMMR prostate cancer had a germline MMR gene mutation that presumably played a causative role in the development of their malignant disease. However, most patients with MSI-H/dMMR A, Tumor mutation burden in mutations per megabase (mut/Mb) and MSIsensor score, a measure of microsatellite instability derived from sequencing data, are given for 1167 tumors from 1033 patients. B, MSIsensor scores were classified as high (Ն10), indeterminate (Ն3 to <10), or low (<3). Tumors with high MSIsensor scores invariably had high TMB and were considered to have high MSI (MSI-H) (orange). Tumors with MSIsensor indeterminate scores were classified as MSI-H or mismatch repair deficient (dMMR) if they had deleterious MMR gene alterations or MMR protein loss on immunohistochemical analysis (orange). Tumors with MSIsensor low scores typically had lower TMBs, with 1 exception that harbored a hotspot mutation in POLE (cyan).
prostate cancer were not germline mutation carriers (eFigure1BintheSupplement). Six of the 32 patients with MSI-H/ dMMR disease underwent sequencing of 2 or more tumors acquired during their disease course ( Figure 3) . Two of these demonstrated somatic acquisition of MSI-H/dMMR status in mCRPC tumors obtained later in their disease course, whereas their earlier tumors showed no evidence of MSI. The earlier tumors had adequate tumor content as quantitated by histopathologic review (50%-70%) and bioinformatically (24%-60%) (eMethods in the Supplement). The remaining 4 patients had evidence of MSI-H/dMMR in all profiled tumors, including 1 patient with a germline PMS2 mutation.
Clinical Characteristics of Patients With MSI-H/dMMR Prostate Cancer
The clinical characteristics of the 32 patients with MSI-H/ dMMR cancer are summarized in eTable 2 in the Supplement. Median age at diagnosis was 64.5 years (range, 39-85 years). One patient had pure small-cell histologic findings. Among the 31 patients with prostate adenocarcinoma, 21 (67.7%) had mCRPC as their last disease state. For those patients, the median time to castration resistance was 8.6 months (range, 1.2-54.2 months) and the median duration of treatment with first-line abiraterone acetate or enzalutamide for mCRPC was 9.9 months (range, 3.0-34.5 months). -T04-IM5   P-0018147-T01-IM6   P-0024219-T01-IM6   P-0000755-T01-IM3   P-0003665-T01-IM5   P-0000964-T03-IM5   P-0022120-T01-IM6   P-0021355-T01-IM6   P-0001325-T01-IM3   P-0014756-T01-IM6   P-0008682-T01-IM5   P-0010034-T01-IM5   P-0000449-T02-IM5   P-0011155-T01-IM5   P-0000449-T01-IM3   P-0007143-T02-IM5   P-0015211-T01-IM6   P-0015837-T01- Responses to Anti-PD-1/PD-L1 Therapy in MSI-H/dMMR mCRPC As of May 2018, 11 of the 32 patients with MSI-H/dMMR had received an anti-PD-1 or anti-PD-L1 agent for mCRPC as monotherapy or in combination with another immunomodulatory agent ( Figure 4) . The remaining 21 patients had not received immune checkpoint blockade owing to death before pembrolizumab approval or had not yet experienced disease progression during standard therapies.
For the 11 patients with mCRPC treated with anti-PD-1/ PD-L1 therapy, duration of therapy ranged from 4.6 to 89 weeks or longer (Figure 4) . Six (54.5%) achieved a decline in prostatespecific antigen (PSA) levels greater than 50%, including 4 with a greater than 99% decline. Eight patients were evaluable for radiographic response; of these, 4 achieved objective responses (eFigure 5 in the Supplement), 1 had stable disease for approximately 6 months, and 3 had radiographic progression as best response. Disease in the remaining 3 patients was inevaluable for radiographic response, owing to early clinical progression or toxic effects in 2 and bone-only disease in 1, although the latter had a durable decline in PSA levels greater than 99%. In total, 5 of 11 patients with MSI-H/dMMR mCRPC (45.5%) continued to receive therapy with durable clinical benefit, 5 (45.5%) had no benefit, and 1 (9.1%) had stable disease for approximately 6 months.
Discussion
The National Comprehensive Cancer Network guidelines for prostate cancer were recently amended to include consideration of MSI-H/dMMR testing and pembrolizumab treatment for MSI-H/dMMR mCRPC in the second-line setting or beyond. 7 However, in its approval of pembrolizumab, the US Food and Drug Administration did not define how MSI-H/dMMR status should be evaluated, and detailed guidance is not provided as part of national guidelines. Some next-generation sequencing assays can assess for MSI-H/dMMR status by interrogating microsatellite loci for evidence of MSI, by identifying mutations and copy number alterations in MMR-associated genes, and by inferring TMB, a phenotypic hallmark of MSI-H/ dMMR tumors. 10,11,13 Next-generation sequencing-based tumor genomic profiling may therefore represent a robust and efficient strategy to identify the subset of patients with prostate cancer who may benefit from anti-PD-1/PD-L1 therapy. Herein, we report the largest experience to date of MSI-H/dMMR characterization in 1346 patients with prostate cancer. Thirty-two (3.1%) of the 1033 patients with evaluable disease had phenotypic evidence of MSI-H/dMMR. We also found that 21.9% of patients with MSI-H/dMMR prostate cancer had a germline mutation in an MMR gene, suggesting that germ- Six patients with MSI-H/dMMR prostate cancer had more than 1 tumor profiled. The time of acquisition of these tumors is indicated relative to the time of acquisition of the first profiled tumor (month 0). Two of the 6 patients (P-0000964 and P-0007143) had evidence of somatically acquired MSI in the latter metastatic castration-resistant tumors. For patient P-0007143, the earlier tumor was a prostate sample acquired at his diagnosis, at which time he had de novo metastatic noncastrate disease. This tumor had a very low MSIsensor score and tumor mutation burden (TMB). One patient (P-0000449) with a germline PMS2 mutation displayed MSI in both matched tumors. IHC indicates immunohistochemical analysis.
line testing should be considered for all patients with MSI-H/ dMMR prostate cancer. We acknowledge that the strict criteria used to define MSI-H/dMMR in our study, including the tumor purity threshold required to report MSIsensor scores, may have resulted in false-negative results in a small number of cases. Our experience suggests that, in clinical practice, it will be of benefit to incorporate information on mutational burden and mutational status of MMR genes in cases in which MSIsensor scores are indeterminate or tumor tissue is of low quality or purity. Sequencing can also identify those patients for whom IHC may be of incremental utility.
A notable finding from our study was that the MSI-H/ dMMR phenotype was acquired somatically later during disease evolution in 2 of 6 patients who underwent longitudinal tumor profiling. Although MSI may have been subclonal in the earlier samples and thus missed owing to tumor heterogeneity, this result indicates that it was not a truncal event and would have been missed if only an older archival sample had been profiled. These data suggest that metastatic tissue may represent the optimal material for assessment of MSI status.
Because the MSI-H/dMMR phenotype is uncommon in prostate cancer, data describing responses to immune checkpoint blockade in this disease subset remain limited. Herein, we report clinical outcomes for the largest group of patients with MSI-H/dMMR mCRPC treated with anti-PD-1/PD-L1 therapy. Overall, 45.5% of patients with MSI-H/dMMR mCRPC derived durable clinical benefit, in line with other MSI-H/ dMMR malignant neoplasms. 5 Because approximately half of patients with MSI-H/dMMR had no response to immunotherapy, future studies should explore mechanisms of resistance in this population, which may involve alterations in the tumor antigen-presenting machinery and tumor-extrinsic factors, including inadequate T-cell activation.
Limitations
Our study has several limitations. It is a single-center retrospective analysis, and the number of patients with MSI-H who were treated with anti-PD-1/PD-L1 therapy is limited. Immunohistochemical analysis was not possible in all patients because of limited tumor tissue. Not all patients had tumors of sufficient quality for MSIsensor analysis, which could be addressed in the future with emerging cell-free DNA platforms.
Conclusions
In conclusion, we propose a comprehensive sequencingbased approach to identify patients with MSI-H/dMMR prostate cancer. Our results demonstrate that anti-PD-1/PD-L1 therapy is associated with meaningful clinical benefit in nearly half of MSI-H/dMMR mCRPC. 
Mutational Signature analysis
Mutational signature analysis was performed as previously described 1, 2 . Briefly, mutations in each tumor were attributed to constituent mutation signatures from a set of 30 signatures previously described 3, 4 . Only signatures with a contribution of 20% or more are shown in Figure   2 . MMR/MSI signatures include signatures 6, 15, 20 and 26. Signature 1 has been attributed to aging. Signatures 12 and 28 are not clearly associated with a biologic process or exposure.
Tumor purity assessment
Tumor purity was estimated by histopathologic review and inferred bioinformatically from the sequencing data using the FACETS algorithm 5 .
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